No human studies have systematically examined the relations among Paco 2 , cerebral blood flow, and the cerebral metabolic rate for oxygen during hypothermic cardiopulmonary bypass. We varied Paco 2 during hypothermic (26-28° C) cardiopulmonary bypass and estimated the cerebral metabolic rate for oxygen by multiplying cerebral blood flow (measured using xenon-133 clearance) by the cerebral arteriovenous difference in oxygen contents. Patients were randomly assigned to either of two methods of managing Paco 2 (uncorrected for body temperature). In group 1 (Paco 2 32-48 mm Hg, n=13) the mean±SD cerebral metabolic rate for oxygen was 0.40 ±0.11 ml O 2 xl00 g'xmin"
P resently, two methods of acid-base management, a-stat and pH-stat, are used during hypothermic cardiopulmonary bypass. 1 The a-stat method maintains Paco 2 at 40 mm Hg and pH at 7.40 when measured at 37° C. The pH-stat method adds CO 2 to the gas inflow of the pump oxygenator to maintain Paco 2 near 40 mm Hg and pH near 7.40 when corrected to body temperature. For example, a Paco 2 measured to be 40 mm Hg in a blood gas analyzer at 37° C would be 27 mm Hg if corrected to a body temperature of 27° C. Clinical studies describing the cerebrovascular effects of Paco 2 during cardiopulmonary bypass have examined the effect of changes in Paco 2 on cerebral blood flow (CBF) but have not investigated the effect of systematic changes in Paco 2 on the cerebral metabolic rate for oxygen (CMRO 2 ). 23 Further characterization of human cerebrovascular responses during cardiopulmonary bypass is essential in the ongoing effort to limit neurologic injury following cardiac surgery. Despite the substantial improvement in neurologic outcome that accompanied early, aggressive efforts to reduce the incidence of embolic events, 4 the incidence of frank stroke still exceeds 1% 5 - 6 and may actually be increasing as progressively older patients are considered to be appropriate candidates for surgery. 7 More significantly, subtle intellectual impairment may follow cardiac surgery in as many as 79% of patients. 8 We performed the following study to characterize a broader range of the CO 2 response curve for CBF and to determine whether changes in CMRO 2 are associated with changes in Paco 2 during hypothermic cardiopulmonary bypass.
Prough et al Hypercarbia Depresses CMRO 2 During CPB hypertension, were screened using carotid Doppler ultrasound to exclude asymptomatic extracranial cerebrovascular occlusive disease. During hypothermic, nonpulsatile cardiopulmonary bypass, patients were randomly assigned either to the a-stat method of Paco 2 management (group 1, « = 13) or to the pH-stat method (group 2, n=12). In each patient, CBF and CMRO 2 were determined at two randomly ordered Paco 2 levels. During each determination, mean arterial blood pressure, pump flow rate, nasopharyngeal temperature, and hematocrit were kept constant. An in-line blood gas analyzer (Bentley Gas-Stat, CDI, Inc., Irvine, Calif.) continuously monitored Paco 2 during cardiopulmonary bypass, and these values were confirmed by intermittent arterial blood gas sampling.
Following premedication with 0.05 mg/kg p.o. lorazepam and 0.10 mg/kg i.m. morphine sulfate, anesthesia was induced with 0.075 mg/kg i.v. fentanyl. The patients were paralyzed with pancuronium or metocurine and ventilated with O 2 to maintain normocarbia before cardiopulmonary bypass. No other drugs were given prior to the completion of CBF determinations; any patient requiring additional drugs for clinical reasons would have been excluded from the study; however, exclusion was not necessary. During cardiopulmonary bypass, 3-4 mg/kg heparin was given as necessary to maintain the activated clotting time at >400 seconds. Extracorporeal circulation was conducted using a membrane oxygenator, a blood-free priming solution, and moderate hemodilution. All patients were cooled to a nasopharyngeal temperature of 25-30° C.
Once each patient's temperature and Paco 2 had been stable for at least 5 minutes, the first CBF determination proceeded by the injection of 3-5 mCi of xenon-133 dissolved in saline into the arterial line of the pump oxygenator. Eight cadmium-telluride gamma detectors per hemisphere measured gamma emissions, and a central VAX 730 computer analyzed the data after correcting each individual clearance curve for changes in the tissue-blood partition coefficient of xenon produced by hypothermia and hemodilution. 9 Data from each detector were analyzed using the CBF 15 method, a noncompartmental calculation similar to the traditional height-over-area method. 10 Data from all detectors in each patient were then averaged to obtain the mean global CBF for each patient at each determination. The second CBF determination in each patient was initiated after a second, stable temperature and Paco 2 level had been maintained for 5 minutes. To minimize the effects of residual radioactivity, the second dose of xenon-133 was increased by 50% and injection was delayed until residual activity was <2.5% of the peak count rate during the first determination. Patients were excluded from analysis if mean arterial blood pressure, pump flow rate, nasopharyngeal temperature, hematocrit, or Paco 2 varied by >5% between determinations.
Jugular bulb venous blood samples were obtained by placing a 20-gauge, 15-cm catheter retrograde into the right internal jugular vein. We estimated CMRO 2 by calculating the difference between the arterial and jugular bulb venous oxygen contents (A-VDO 2 ) and multiplying this by the mean global CBF. Blood samples were analyzed at 37° C in an IL 813 blood gas analyzer and at 37° C in an IL 282 CO-oximeter (Instrumentation Laboratory, Lexington, Mass.). We calculated arterial and jugular bulb venous oxygen contents from the temperatureuncorrected blood gas and CO-oximeter data using the standard formula C I O 2 =P x O 2 x 0.003l+S x O 2 x Hgbxl.34, where C X O 2 is arterial or venous oxygen content, P X O 2 is arterial or venous oxygen tension, Hgb is hemoglobin concentration, and S X O 2 is measured oxygen saturation.
Data (expressed as mean±SD) were analyzed using multivariate repeated-measures analysis of variance (ANOVA) for the primary variables CBF, A-VDO 2 , and CMRO 2 . Three-way repeated-measures ANOVA was initially performed to confirm the necessity of randomly varying the order of the Paco 2 levels. The factors analyzed were group, Paco 2 level, and order of Paco 2 level. Two-way repeated-measures ANOVA was then performed for the two variables group and Paco 2 level. When an interaction occurred between the two variables, multivariate repeated-measures ANOVA was performed for each group to look for an effect of Paco 2 level and for each Paco 2 level to look for an effect of group. Where significant differences existed, Tukey's multiple comparison procedure was applied to determine at what intervals these differences occurred. 11 An a of 0.05 was used for all statistical procedures. Data for controlled variables were calculated for descriptive purposes only and were not analyzed statistically.
Results
All controlled variables except Paco 2 were comparable at both Paco 2 levels in both groups (Table 1) . Paco 2 differed by experimental design.
As demonstrated by a significant three-way interaction (/?<0.02) among group, Paco 2 level, and order of Paco 2 level, the randomization of order was necessary. There was no significant effect of order alone. Changes in CBF with alterations in Paco 2 are shown in Figure 1 . CBF in group 2 was significantly greater than that in group 1 (p<0.05) at both Paco 2 levels. Within each group, CBF was significantly greater at the high Paco 2 level (/><0.05 in each group).
The increase in CBF as Paco 2 increased was associated with a decrease in A-VDO 2 ( Figure 2) . Within each group, Paco 2 level significantly influenced A-VDO 2 (/?<0.05 in group 1 and/j<0.001 in group 2).
Like CBF and A-VDO 2 , CMRO 2 also depended on Paco 2 . There was no three-way interaction among group, Paco 2 level, and order of Paco 2 level for CMRO 2 . In group 1, CMRO 2 did not differ between Paco 2 levels ( Figure 3) . However, CMRO 2 in group 2 17 approximately 10% of that in normal, awake humans. 19 The surprisingly low CMRO 2 results from reductions in both CBF and A-VDO 2 to below those found in normothermic humans. Possible explanations for these levels include the effects of fentanyl, hypothermia, and hemodilution. In response to moderate hemodilution, CBF increases sufficiently to offset approximately 50% of the decline in arterial oxygen content. 20 Therefore, in a hypothetical, spontaneously perfusing, normothermic human, a decline in arterial oxygen content from 20 to 10 ml x 100 ml" 1 would be expected to increase CBF from 50 to 75 mix 100 g^xmin" 1 . If CMRO 2 remained constant at 3.5 mix 100 g^xmin" 1 , A-VDO 2 would decline from 7.0 to approximately 4.7 mix 100 ml" 1 . Jugular venous oxygen saturation would also decline from 65% to approximately 53%. In our study, A-VDO 2 (which is multiplied by CBF to calculate CMRO 2 ) during cardiopulmonary bypass at any given Paco 2 level is similar to that reported by Wollman et al 21 two decades ago. Our study further suggests that greater increases in Paco 2 depress CMRO 2 by nearly 50%. The mechanism of this substantial reduction in CMRO 2 cannot be determined from this study but may involve the anesthetic/narcotic effect of CO 2 . At a partial pressure of 245 mm Hg, CO 2 produces surgical anesthesia in normothermic dogs. 22 Less severe hypercarbia depresses CMRO 2 in normothermic, anesthetized animals. 23 -25 Therefore, our data suggest that the pH-stat method of managing Paco 2 and pH produces cerebral metabolic effects analogous to acute hypercarbia. Dependence of CMRO 2 on Paco 2 in humans has also been suggested by Obrist et al 26 based on studies in patients with head injuries. However, our data do not clarify whether relative hypercarbia primarily reduces activity-related or basal CMRO 2 .
Our data also suggest that cerebral metabolism is depressed to a surprisingly great extent in humans during hypothermic cardiopulmonary bypass. In animals undergoing cardiopulmonary bypass, systemic oxygen consumption declines by a factor of 2.8 ±0.3 for each 10° C decline in body temperature. 27 In rapidly cooled patients, systemic oxygen consumption changes similarly. 28 In nonhuman primates, CMRO 2 declined from 5.9 mix 100 g^xmin" 1 at 37° C to 1.8 mix 100 g^xmin" 1 at a body temperature of 27° C, with individual animals having CMRO 2 values as low as 0.5 and 0.9 mix 100 g" 1 xmin" 1 at body temperatures of 26.5° and 25° C, respectively. 29 However, our calculation of CMRO 2 , as those of Murkin et al, 17 Woodcock et al, 30 and Obrist et al, 26 is based on the multiplication of mean cortical blood flow by the difference in oxygen contents of arterial and jugular bulb blood. Implicit in the use of that calculation is the assumption that CBF and CMRO 2 change in quantitatively similar manners in the cortex and deeper structures. Current technology does not permit validation of this concept in humans during cardiopulmonary bypass; however, measurements obtained using a modification of the Kety-Schmidt technique demonstrated a mean CMRO 2 during cardiopulmonary bypass of 0.49 mix 100 g^xmin" 1 at a temperature-uncorrected Paco 2 approximating 46 mmHg at 26.9°C. 31 The authors did not report adjustment of the argon tissue-blood partition coefficient for changes due to hemodilution and hypothermia. Analysis of xenon-133 clearance data during cardiopulmonary bypass demonstrates excellent correlation between the CBF 15 technique and the classical stochastic method. 32 No study has systematically evaluated neuropsychologic outcome as a function of CBF or CMRO 2 across the entire range of Paco 2 values encompassed by the a-stat and pH-stat methods. Although the pH-stat method simultaneously depresses CMRO 2 and increases CBF, the increase in CBF might increase the proportion of emboli directed to the cerebral circulation and might create intracerebral steals. Although they have been described in humans undergoing carotid endarterectomy, 33 intracerebral steals have not been demonstrated during cardiopulmonary bypass. 34 In summary, during hypothermic cardiopulmonary bypass (nasopharyngeal temperature of 25-30° C), a temperature-uncorrected Paco 2 of 68 mm Hg reduces CMRO 2 to approximately one-half that at a Paco 2 of 45 mm Hg. Our data additionally confirm a progressive increase in CBF as Paco 2 increases. Further studies must clarify the significance and application of these findings to postoperative neurologic deficits following cardiac surgery. D S Prough, A T Rogers, D A Stump, S A Mills, G P Gravlee and C Taylor
